An important study by researchers in Finland and the UK has shown for the first time that myocardial infection can be an infectious disease. This discovery challenges the traditional understanding of the pathogenesis of myocardial infection and opens new avenues for treatment, diagnosis and even vaccine development.
According to a recently published research, infection can trigger myocardial infection. Using a range of sophisticated procedures, research has shown that in coronary artery disease, cholesterol -containing atroscalotic plates have ported the gelatin, the bacteria for decades or even decades or even decades. Bacteria inside the biofilm is shielded with both the patient’s immune system and antibiotics as they cannot enter the biofelmics.
Viral infection or any other external stimulation can activate biofoma, which reacts to bacterial spread and inflammation. Inflammatory plaque fibers can cause bursting in the cap, which in turn results in the formation of thrombus and ultimately myocardial infection.
Professor Pika Carahon, who guides this study, notes that so far, it was assumed that the incidence of coronary artery disease was only launched by oxidized low -density lipoprotein (LDL), which the body recognizes as a foreign structure.
“The bacterial involvement in coronary artery disease has long been suspected of being involved, but has lacked direct and reliable evidence. Our study has shown the presence of genetic substance – DNA – from Ethoscalotrick, from an oral bacteria.”
These results were confirmed by developing an antibody targeting the discovered bacteria, which unexpectedly revealed the biofilm structure in the arterial tissue. The bacterial bacteria from biofelm was seen in cases of myocardial infection. The body’s immune system responded to these bacteria, which triggered inflammation, which broke the plank from cholesterol.
Observations pave the way for the development of novel diagnostic and treatment strategies for myocardial infection. In addition, they advance the possibility of preventing coronary artery disease and myocardial infection through vaccination.
The study was conducted by Tempir and Uloo Universities, Finnia Institute for Health and Welfare and Oxford University. Tissue samples were obtained from people who suddenly died of cardiac deaths, as well as ethrosclerosis patients who were conducting surgery to clear carotide and peripheral arteries.
This research is part of the EU financing research project comprising 11 countries. Important funding was also provided through the Finnish Foundation for Calculation Research and Jane and Autos Aerco Foundation.
Research article “Varidance Streptococcal Biofloom has been helpful in avoiding immune detection and inflammation and bursting of ethroscalotic plates” Journal of the American Heart Association.
